Scholars Central

ArticlePublished 3 Aug 2020

Anlotinib combined with temozolomide therapy for patient of diffuse midline glioma: A case report

Authors: Chi Hu, Minwei Fang, Qingsheng Xu

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Diffuse midline glioma with histone H3-K27M mutation is a brand-new tumor entity according to 2016 edition of WHO classification. As diffuse midline gliomas are aggressive and incurable brain tumors, conventional treatment can hardly work, leading to the poor outcome of patients. Anlotinib is a newly developed oral small-molecule RTK inhibitor that targets VEGFR1, VEGFR2/KDR, VEGFR3, c-Kit, PDGFR-α, and FGFRs. Anlotinib can inhibit both tumor angiogenesis and tumor cell proliferation. It can inhibit more targets and has a better antiangiogenic activity than other target drugs. Therapeutic efficacy of anlotinib has been proved in advanced NSCLC, advanced STS, metastatic renal cell carcinoma, and advanced medullary thyroid cancer. Only mild side effects were discovered in these studies. This case report presents a 51-year-old man suffering from diffuse midline glioma with histone H3-K27M mutation. After three cycles of temozolomide, the patient received radiotherapy with total DT of 5400cGy/20F, 200cGy/F, 5F/W, accompanied by chemotherapy of TMZ 75 mg/m2 , then therapy with bevacizumab 5 mg/kg, Considering it was inconvenient for bevacizumab injection, we recommended adjusting the treatment plan to oral administration of anlotinib (10 mg qd d1-14, 21 days a cycle) plus TMZ (200 mg/m2, d1-5, 28 days a cycle). After 8 months treatment of anlotinib combined with temozolomide, MRI of this patient showed that the mass was significantly reduced compared to that before targeted therapy. Our case firstly reported that anlotinib combined with TMZ was used for patients with diffuse midline glioma with histone H3-K27M mutation. Up till now, this patient has survived for 20 months.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Medicine and Medical Sciences.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Medicine and Medical Sciences
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Chi Hu”
  • BylineArticles whose byline prints “Minwei Fang”
  • BylineArticles whose byline prints “Qingsheng Xu”